Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
140.21(c) 136.39(c) 126.57(c) 121.02(c) 121.64(c) Last
1 385 566 1 654 782 1 655 263 2 377 644 3 014 556 Volume
+3.00% -2.72% -7.20% -4.38% +0.51% Change
More quotes
Financials (USD)
Sales 2021 1 747 M - -
Net income 2021 -586 M - -
Net Debt 2021 776 M - -
P/E ratio 2021 -35,5x
Yield 2021 -
Sales 2022 2 161 M - -
Net income 2022 -444 M - -
Net Debt 2022 1 096 M - -
P/E ratio 2022 -48,3x
Yield 2022 -
Capitalization 20 568 M 20 568 M -
EV / Sales 2021 12,2x
EV / Sales 2022 10,0x
Nbr of Employees 4 900
Free-Float 93,4%
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect... 
Sector
Biotechnology & Medical Research
Calendar
03/09 | 09:10amPresentation
More about the company
Notations Surperformance© of Exact Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
All news about EXACT SCIENCES CORPORATION
03/03INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Exact Sciences
MT
02/18EXACT SCIENCESá : UBS Adjusts Exact Sciences PT to $154 From $140, Maintains Neu..
MT
02/17EXACT SCIENCESá : Cowen & Co Adjusts Exact Sciences PT to $180 From $150, Mainta..
MT
02/17EXACT SCIENCESá : SVB Leerink Adjusts Exact Sciences' Price Target to $180 From ..
MT
02/16EXACT SCIENCESá : Management's Discussion and Analysis of Financial Condition an..
AQ
02/16EXACT SCIENCES : 4Q Earnings Snapshot
AQ
02/16EXACT SCIENCESá : to Acquire Ashion Analytics from City of Hope Affiliate TGen; ..
MT
02/16EXACT SCIENCESá : Swings to Q4 Net Loss of $2.79 a Share; Revenue Rises Ahead of..
MT
02/16EXACT SCIENCESá : Earnings Flash (EXAS) EXACT SCIENCES Reports Q4 Revenue $466.3..
MT
02/10THE TRUTH ABOUT CANCER : Debunking Five Myths about the Big C
PU
01/28EXACT SCIENCESá : Truist Starts Exact Sciences at Buy With $226 Price Target
MT
01/21EXACT SCIENCESá : SVB Leerink Adjusts Exact Sciences' Price Target to $170 From ..
MT
01/15EXACT SCIENCES CORPá : Change in Directors or Principal Officers (form 8-K)
AQ
01/13EXACT SCIENCESá : Licenses Targeted Digital Sequencing Method in Cancer Screenin..
MT
01/12EXACT SCIENCESá : Oppenheimer Adjusts Price Target for Exact Sciences to $161 Fr..
MT
More news
News in other languages on EXACT SCIENCES CORPORATION
2020EXACT SCIENCES CORPORATIONá : Veröffentlichung des Jahresergebnisses
2020EXACT SCIENCES CORPORATIONá : publication des résultats annuels
2019STOCK MARKET PARIS : Attention, semaine très chargée !
2019EN DIRECT DES MARCHESá: Sanofi, Airbus, Air France KLM, CNP, Refinitiv, Mylan..
2017EXACT SCIENCES CORPORATIONá : Veröffentlichung des Halbjahresergebnisses
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 166,94 $
Last Close Price 121,64 $
Spread / Highest target 85,8%
Spread / Average Target 37,2%
Spread / Lowest Target -37,5%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION-4.47%20 568
GUARDANT HEALTH, INC.3.31%13 585
BGI GENOMICS CO., LTD.1.61%8 244
INVITAE CORPORATION-18.34%6 714
ADAPTIVE BIOTECHNOLOGIES CORPORATION-26.13%5 879
IOVANCE BIOTHERAPEUTICS, INC.-31.53%4 756